Zentalis Pharmaceuticals, Inc.
ZNTL
$4.18
$0.030.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -124.13M | -137.06M | -149.32M | -162.78M | -224.19M |
| Total Depreciation and Amortization | 628.00K | 739.00K | 899.00K | 1.06M | 1.23M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.54M | 20.20M | 29.23M | 31.54M | 70.69M |
| Change in Net Operating Assets | -11.60M | -9.12M | -14.82M | -20.91M | 747.00K |
| Cash from Operations | -125.57M | -125.25M | -134.01M | -151.09M | -151.52M |
| Capital Expenditure | -34.00K | -- | 0.00 | 0.00 | -181.00K |
| Sale of Property, Plant, and Equipment | 693.00K | 698.00K | 569.00K | 569.00K | 70.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.50M | 130.93M | 130.89M | 150.81M | 155.60M |
| Cash from Investing | 121.16M | 131.62M | 131.46M | 151.38M | 155.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.84M | 5.69M | 304.00K | 281.00K | 290.00K |
| Repurchase of Common Stock | -11.43M | -9.98M | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.59M | -4.28M | 304.00K | 281.00K | 290.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.00M | 2.09M | -2.25M | 569.00K | 4.26M |